Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes

Diabetes Care

Volumn 21, Issue 9, 1998, Pages 1462-1469

  Horion, Edward S ^a   Whitehouse, Fred ^b   Ghazzi, Mahmoud N ^c   Venable, Tom C ^c   Whitcomb, Randall W ^c  

^a JOSLIN DIABETES CENTER   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; C PEPTIDE; GLIBENCLAMIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 3543018475     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.9.1462     Document Type: Article

References (26)

1. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Diabetes Statistics. Bethesda, MD, National Institutes of Health, 1995, p. 1-4(NIH Publ. No, 96-3926)
2. Harris MI, Hadden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 years. Diabetes 36:523-534, 1987
3. Rubin RJ, Altman WM, Mendelson DN: Health care expenditures for people with diabetes mellitus. J Clin Endocrinol Metab 78:809A-F, 1994
4. Olefsky JM: Pathogenesis of insulin resistance and hyperglycemia in non-insulin-dependent diabetes mellitus. Am J Med 79 (Suppl. 3B): 1-7, 1985
5. Reaven GM: Insulin secretion and insulin action in non-insulin-dependent diabetes mellitus: which defect is primary? Diabetes Care 7 (Suppl 1): 17-24, 1984
6. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 20 (Suppl. 1):S4-S13, 1997
7. Gerlich JE: Oral hypoglycemic agents. N Engl J Med 321:1231-1245, 1989
8. Groop LC: Sulfonylureas in NIDDM. Diabetes Care 15:737-754, 1992
9. Tal A: Oral hypoglycemic agents in the treatment of type II diabetes. Am Fam Physician 48:1089-1095, 1993
10. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
11. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study Diabetes Res Clin Pract 28:103-117, 1995
12. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes, Diabetes 45:1661-1669, 1996
13. Henry RR: Effects of troglitazone on insulin sensitivity Diabet Med 13 (Suppl. 6):S148-S150, 1996
14. Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouchi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y, Baba S: A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with noninsulin dependent diabetes mellitus. Diabetes Res Clin Pract 11:147-154, 1991
15. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y, Nawata H: Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11:685-691, 1994
16. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy Diabetes Care 19:151-156, 1996
17. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
18. Ghazzi M, Ferez J, Antonucci T, Driscoll J, Huang S, Faja B, The Troglitazone Study Group, Whitcomb R: Cardiac and glycemic benefit of troglitazone treatment in NIDDM. Diabetes 46:433-439, 1997
19. Whitcomb RW, Saltiel AR: Section review: oncologic, endocrine and metabolic: thiazolidinediones. Exp Opin Invest Drugs 4:1299-1309, 1995
20. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
21. American Diabetes Association: Nutritional recommendation and principles for individuals with diabetes mellitus. Diabetes Care 14 (Suppl. 2):20-27, 1991
22. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 20 (Suppl. 1):S5-S13, 1997
23. Wood J: Management of primary hyperlipidemia. Drug Therapy 332:1491-1498, 1995
24. Eisenberg S: Lipoprotein abnormalities in hypertriglyceridemia: significance in atherosclerosis. Am Heart J 113:555-561, 1987
25. The DCCT Research Group: Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care 11:567-573, 1988
26. Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone treatment (Letter). N Engl J Med 338:916-917, 1998